Avantor, Inc. ($AVTR) Stock Forecast: Up 5.2% Today

What is Avantor, Inc.?

Avantor, Inc. (AVTR) is a company listed on the New York Stock Exchange (NYSE) specializing in the bioscience and medtech industries. The company has demonstrated noteworthy positive momentum in the market.

Why is Avantor, Inc. going up?

AVTR stock is up 5.2% on May 6, 2026 15:16

• An investigation into potential corporate misconduct by Avantor's executives may have initially caused unease among investors, resulting in a stock price decline over the past year.
• Director Simon Dingemans' recent acquisition of company stock, following Avantor's strong performance in Q1 2026, is likely to have inspired investor confidence and had a positive effect on the stock price.
• The allocation of restricted stock units and stock options to EVP Ludovic Brellier as part of his compensation package may have indicated to the market the company's vision for long-term growth and its dedication to retaining top talent.
• Insider actions, such as the director's purchase of shares on the open market and the EVP's completion of ownership forms, may have additionally increased investor faith in Avantor's leadership and future prospects, contributing to the favorable market movement.

AVTR Price Chart

AVTR Technical Analysis

AVTR News

Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Avantor, Inc. (AVTR) shareholders who purchased securities prior to March 5, 2024, and continue to hold them. The investigation concerns potential corporate wrongdoing by Avantor's officers and/or directors. The firm encourages affected investors to contact them for more information, noting that they represent investors on a contingency fee basis.

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-avantor-inc.-avtr-1155346

Avantor (NYSE: AVTR) EVP Ludovic Brellier awarded RSUs and 246,002 stock options

Avantor, Inc. EVP Ludovic Brellier was granted 146,566 restricted stock units and 246,002 stock options as part of his compensation. These equity awards, which are not open-market transactions, will vest in three equal annual installments starting May 1, 2027. The stock options have an exercise price of $8.76 per share and expire on May 1, 2036.

https://www.stocktitan.net/sec-filings/AVTR/form-4-avantor-inc-insider-trading-activity-cda043306a99.html

Avantor director Simon Dingemans buys $203,500 in company stock

Avantor director Simon Dingemans acquired 25,000 shares of company stock for $203,500 on May 1, 2026, bringing his total indirect holdings to 25,000 shares and direct holdings to 6,225 shares. This purchase occurred after Avantor exceeded Q1 2026 financial expectations with an EPS of $0.17 and revenue of $1.581 billion, positively impacting investor sentiment despite a 36% stock price decline over the past year.

https://m.investing.com/news/insider-trading-news/avantor-director-simon-dingemans-buys-203500-in-company-stock-93CH-4661560?ampMode=1

Avantor (AVTR) director adds 25,000 shares via open-market purchase

Avantor, Inc. (AVTR) director Simon Dingemans reported an open-market purchase of 25,000 shares of common stock at $8.14 per share, totaling $203,500. These shares are held indirectly by his spouse, in addition to his direct holding of 6,225 shares. The Form 4 filing confirmed this positive insider activity, indicating confidence from the director.

https://www.stocktitan.net/sec-filings/AVTR/form-4-avantor-inc-insider-trading-activity-4364da673052.html

Avantor (NYSE: AVTR) EVP files initial Form 3 ownership

Avantor, Inc.'s Executive Vice President of Bioscience & Medtech, Ludovic Brellier, has filed an initial Form 3 with the SEC, establishing his status as an insider. The filing indicates his beneficial ownership of securities but reports no actual buy or sell transactions or derivative positions at this time. This initial report serves to disclose his relationship with the company rather than any trading activity.

https://www.stocktitan.net/sec-filings/AVTR/form-3-avantor-inc-initial-statement-of-beneficial-ownership-e92a25bd2d6d.html

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 6.3% Today

SBA Communications Corporation ($SBAC) Stock Forecast: Down 1.8% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Up 10.6% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.1% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Up 5.1% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.0% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 5.6% Today

Centene Corporation ($CNC) Stock Forecast: Up 5.4% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 7.0% Today

Avantor, Inc. Price History

29.00.2026 - AVTR Stock was down 5.2%

• The bearish movement in AVTR's stock price today can be attributed to several factors:
• Allegations of misrepresentation and increased competition leading to a federal securities lawsuit may have raised concerns among investors, impacting the stock negatively.
• Insider purchases by Sector Gamma AS and two directors, while initially positive, were overshadowed by Avantor missing its quarterly EPS estimates and providing lower-than-expected guidance for FY2025.
• The upcoming release of Q4 and full-year 2025 financial results, along with discussions on the outlook for 2026, has likely created uncertainty and caution among investors, contributing to the bearish sentiment.
• The ongoing investigations by multiple law firms into potential breaches of fiduciary duties by Avantor's officers and directors have added to the negative sentiment surrounding the stock, further pressuring its price downwards.

21.03.2026 - AVTR Stock was up 5.0%

• The bullish movement in AVTR's stock can be attributed to the company's strategic decision to localize advanced microbial and stability testing at its St. Louis manufacturing site, aiming to streamline supply chain operations and improve turnaround times for biopharma customers.
• Strong near and mid-term sentiment, along with specific AI-generated trading strategies emphasizing a favorable risk-reward setup, likely attracted investors looking for short to mid-term gains.
• AVTR's expansion of quality control capabilities to accelerate biopharma manufacturing, coupled with its emphasis on recurring revenue from consumables and operational efficiencies, reinforces investor confidence in the company's growth potential and market position.
• Despite the ongoing securities investigation by a law firm, the positive market sentiment surrounding AVTR's strategic initiatives and market leadership in life sciences appears to have overshadowed concerns, driving the bullish movement in the stock.

30.03.2026 - AVTR Stock was up 5.4%

• A significant stake by an investor in Avantor suggests confidence in the company's future prospects, potentially improving investor sentiment.
• Avantor's strong Q1 2026 results, attributed to enhanced execution in key segments and the success of its "Revival" transformation program, may have contributed to the positive stock movement.
• Despite challenges with revenue growth and declining margins in recent years, Avantor's reaffirmed full-year guidance and positive earnings call have reassured investors about the company's turnaround efforts, leading to the stock price increase.
• Although flat net sales year-over-year and some financial metric declines were reported in the 10-Q, the company's positive outlook for the year has outweighed these aspects, driving the bullish market movement.

30.03.2026 - AVTR Stock was up 5.6%

• Strong Q1 2026 earnings were reported by Avantor, surpassing expectations with an EPS of $0.17 and revenue of $1.581 billion, leading to a 6.49% surge in premarket trading.
• The company's initiatives under "Revival," which target operational stability and execution improvements, are yielding positive results, particularly within the BMP segment.
• Institutional confidence in Avantor's future growth prospects is highlighted by Vanguard's disclosure of a 5.29% stake in the company.
• Despite concerns regarding stagnant revenue growth over the past five years, Avantor's reiteration of full-year guidance and anticipated organic revenue growth in the latter half of 2026 have reinforced investor confidence, propelling a bullish trend in the stock.

06.02.2026 - AVTR Stock was down 6.1%

• An "underweight" rating on Avantor reiterated by Barclays reflects concerns about future earnings, despite the company surpassing recent earnings expectations slightly. This negative sentiment from analysts may have influenced the stock's bearish movement.
• The negative forecast for Avantor's Q1 2026 earnings by Zacks Research, along with multiple analysts lowering price targets, has added pressure on the stock.
• Despite a high institutional ownership, the significant decrease in stake by the Teachers Retirement System of The State of Kentucky might suggest a lack of confidence in Avantor's future prospects, further impacting the stock price negatively.
• Avantor's historical poor earnings performance, continuously missing EPS and revenue estimates, along with ongoing financial challenges such as low return on equity and declining net profit, have likely heightened investor worries and contributed to the stock reaching a new low.

11.01.2026 - AVTR Stock was down 16.5%

• An investigation into potential corporate wrongdoing by Avantor and its officers/directors may have caused concerns among investors, resulting in a sell-off.
• Analysts' expectation of a 2.9% year-over-year revenue decrease in the upcoming earnings report could have influenced the negative sentiment towards the stock.
• Bessemer Group Inc.'s significant reduction in its stake in Avantor, Inc. by selling over 7 million shares likely exacerbated the downward pressure on the stock.
• Avantor's history of underperforming in revenue estimates compared to the sector may have prompted investors to approach the stock cautiously, leading to today's bearish movement.

24.03.2026 - AVTR Stock was up 5.5%

• The appointment of Ludovic Brellier as the Executive Vice President, Bioscience & Medtech Products, and Chief Transformation Officer has generated positivity around Avantor, signaling a strategic shift towards improving operational performance and implementing company-wide transformation.
• Analysts predict a return to profitability for Avantor this year post the leadership changes and transformation efforts, which likely bolstered investor confidence and contributed to the stock's upward momentum.
• The forthcoming departure of the current EVP, Benoit Gourdier, scheduled by year-end 2026 to assume an integration support role, may be seen as a move to streamline operations and position the company for future growth, further instilling investor optimism in Avantor's potential.
• An investigation into potential corporate misconduct at Avantor before March 5, 2024, initiated by Bronstein, Gewirtz & Grossman, LLC, could have sparked shareholder concerns initially. However, the positive leadership developments and growth strategies appear to have outweighed these apprehensions, driving the bullish market performance.

12.01.2026 - AVTR Stock was down 5.2%

• AVTR stock plummeted post-Q4 earnings disclosure due to the conservative 2026 forecast and a Q4 revenue decline.
• The company's "Revival" initiative aimed at enhancing manufacturing, supply chain, and digital platforms did not capture investor interest, resulting in subdued market sentiment and a stock dip.
• An uptick in put options trading, signaling potential higher volatility or downside for AVTR stock, showcases mixed investor sentiment.
• Despite favorable financial performance, including surpassing earnings expectations and a significant insider buy-in, apprehensions regarding future guidance and market conditions contributed to the downward movement in AVTR stock.

23.03.2026 - AVTR Stock was down 8.7%

• Avantor's CEO, Emmanuel Ligner, emphasized the company's potential in the pharmaceutical and life science sectors. However, market sentiment may have been influenced by concerns regarding revenue pressure and margin compression despite positive strategic insights.
• The expansion of Avantor's Masterflex brand to enhance fluid management for bioprocessing was viewed positively. Nevertheless, investor caution may have stemmed from perceived weakness in the company's long-term outlook in technical analysis.
• Introducing advanced microbial and stability testing capabilities at Avantor's St. Louis site to simplify the supply chain and improve turnaround times might have been overlooked amid doubts about the company's capacity to capture outsourcing demand and fortify its financial prospects.
• The indication of a weak long-term outlook for Avantor in a technical analysis report could have contributed to the stock's bearish performance today, overshadowing positive developments in the company's strategic initiatives and product portfolio expansions.

12.02.2026 - AVTR Stock was down 5.0%

• The decline in Avantor's stock price may be linked to an ongoing securities investigation, potentially causing concerns among investors regarding the company's integrity.
• Despite recent insider purchases and increased stakes by institutional investors such as Barrow Hanley Mewhinney & Strauss LLC and American Century Companies Inc., the negative impact of the investigation news likely overshadowed these positive events.
• The market sentiment might have been influenced by differing analyst ratings, with an overall "Hold" consensus on Avantor, indicating a lack of strong buy recommendations that could have bolstered investor trust.
• While there was a notable rise in institutional ownership, including significant share acquisitions by WINTON GROUP Ltd, this positive development may have been outweighed by the lingering impact of the ongoing investigation, leading to the stock's bearish trend.

09.03.2026 - AVTR Stock was down 5.7%

• The decline in AVTR's stock may be linked to profit-taking by investors post the company's Q1 earnings meeting expectations. Although meeting projections, investors hoped for more robust performance.
• Insider trading activity by the SVP & Chief Accounting Officer, considered as a compensation grant, could have sparked investor concerns regarding the company's future prospects or internal matters.
• The uncertainty surrounding the upcoming earnings report on April 29, 2026, may be fostering caution among traders, contributing to AVTR's stock's downward trend.
• Comparisons with competitors regarding financial health and efficiency metrics might be impacting investor sentiment and influencing AVTR's stock's bearish movement.

06.04.2026 - AVTR Stock was up 5.2%

• An investigation into potential corporate misconduct by Avantor's executives may have initially caused unease among investors, resulting in a stock price decline over the past year.
• Director Simon Dingemans' recent acquisition of company stock, following Avantor's strong performance in Q1 2026, is likely to have inspired investor confidence and had a positive effect on the stock price.
• The allocation of restricted stock units and stock options to EVP Ludovic Brellier as part of his compensation package may have indicated to the market the company's vision for long-term growth and its dedication to retaining top talent.
• Insider actions, such as the director's purchase of shares on the open market and the EVP's completion of ownership forms, may have additionally increased investor faith in Avantor's leadership and future prospects, contributing to the favorable market movement.